References:
1. WHO Coronavirus (COVID-19) Dashboard; https://covid19/who/int/.
2. Acosta-Coley I, Cervantes-Ceballos L, Tejeda-Benítez L, et al.
Vaccines platforms and COVID-19: what you need to know. Trop Dis Travel
Med Vaccines. 2022;8(1):20
3. Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of
ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta
(B.1.617.2) variant surge in India: a test-negative, case-control study
and a mechanistic study of post-vaccination immune responses. Lancet
Infect Dis. 2022;22(4):473-482.
4. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell
responses 1 year after infection in people recovered from COVID-19: a
longitudinal cohort study. Lancet Microbe. 2022;3(5):e348-e356.
5. Guerrera G, Picozza M, D’Orso S, et al. BNT162b2 vaccination induces
durable SARS-CoV-2-specific T cells with a stem cell memory phenotype.
Sci Immunol. 2021;6(66):eabl5344.
6. Bertoletti A, Le Bert N, Tan AT. SARS-CoV-2-specific T cells in the
changing landscape of the COVID-19 pandemic. Immunity.
2022;55(10):1764-1778.
7. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV:
Implications for vaccine development against MERS-CoV. Antiviral Res.
2017;137:82-92.
8. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory
and back. Immunity. 2010;33(4):451-463.
9. Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector
Functions, and CAR-T Immunotherapy. Cancers (Basel). 2016;8(3):36.
10. Impact of surge in China COVID-19 cases on epidemiological situation
in EU/EEA. Available from
https://www.ecdc.europa.eu/en/news-events/impact-surge-china-covid-19-cases.
Accessed January 2022.
11. Ministry of Health and Family Welfare – GOI”. Available from
https://www.mohfw.gov.in. Accessed April 24, 2023.
12. Tartof SY, Slezak JM, Puzniak L, et al. Analysis of mRNA COVID-19
Vaccine Uptake Among Immunocompromised Individuals in a Large US Health
System. JAMA Netw Open. 2023;6(1):e2251833.
13. Furukawa K, Tjan LH, Kurahashi Y, et al. Assessment of Neutralizing
Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the
BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open. 2022;5(5):e2210780.
14. Nickel O, Rockstroh A, Wolf J, et al. Evaluation of the systemic and
mucosal immune response induced by COVID-19 and the BNT162b2 mRNA
vaccine for SARS-CoV-2. PLoS One. 2022;17(10):e0263861
15. Trombetta CM, Marchi S, Leonardi M, et al. Evaluation of antibody
response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine
in a correctional facility. Hum Vaccin Immunother. 2022;18(7):2153537.
16. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces
immunological T cell memory able to cross-recognize variants from Alpha
to Omicron. Cell. 2022;185(5):847-859.e11.
17. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response
to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med.
2021;385(24):e84.
18. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune
dysfunction: distinctive features and clinical relevance. J Hepatol.
2014;61(6):1385-1396.
19. Lario M, Muñoz L, Ubeda M, et al. Defective thymopoiesis and poor
peripheral homeostatic replenishment of T-helper cells cause T-cell
lymphopenia in cirrhosis. J Hepatol. 2013;59(4):723-730.
20. Goel A, Verma A, Tiwari P, et al. Serological Immune Response
Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver
Cirrhosis. Vaccines (Basel). 2022;10(11):1837.
21. Mohammed AH, Blebil A, Dujaili J, Rasool-Hassan BA. 2020. The risk
and impact of COVID-19 pandemic on immunosuppressed patients: Cancer,
HIV, and solid organ transplant recipients. AIDS Rev .
22:151–157.
22. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in
immunocompromised patients: systematic review and meta-analysis. BMJ.
2022;376:e068632.
23. Costiniuk CT, Singer J, Lee T, et al. COVID-19 vaccine
immunogenicity in people with HIV. AIDS. 2023;37(1):F1-F10.
24. Reeg DB, Hofmann M, Neumann-Haefelin C, Thimme R, Luxenburger H.
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals
with Cancer, HIV or Solid Organ Transplants. Pathogens. 2023;12(2):244.
25. Good practice statement on the use of second booster doses for
COVID-19 vaccines 18 August 2022 Background [Internet]. Available
from: https://www.who.int/groups/strategic-advisory.
26. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu Rev
Immunol. 2004;22:745-763.
27. Sharma P, Kumar A, Anikhindi S, et al. Effect of COVID-19 on
Pre-existing Liver disease: What Hepatologist Should Know?. J Clin Exp
Hepatol. 2021;11(4):484-493.
28. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response
in cirrhosis and liver transplantation. J Infect Dis.
2000;181(2):757-760.
29. Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A, et al.
Response to vaccination against hepatitis B virus with a schedule of
four 40-μg doses in cirrhotic patients evaluated for liver
transplantation: factors associated with a response. Transplant Proc.
2012;44(6):1499-1501.
30. Thieme CJ, Anft M, Paniskaki K, et al. The Magnitude and
Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in
Transplant Population Is Similar to the General Population Despite
Immunosuppression. Transplantation. 2021;105(10):2156-2164.
32. Feng S, Phillips DJ, White T, et al. Correlates of protection
against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med.
2021;27(11):2032-2040.